Global Markets Tumble as US-Iran Tensions Escalate, Oil Surges 
Asian Markets Mixed as Oil Volatility and Inflation Fears Weigh on Sentiment 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
Gold Prices Stabilize but Head for Worst Weekly Drop in Six Years Amid Iran War Inflation Fears 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Oil Prices Surge Amid Trump's Iran Ultimatum Over Strait of Hormuz 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
U.S. Markets Post Fourth Straight Weekly Loss Amid Middle East Escalation 
Sinopec Posts 36.8% Net Profit Drop in 2025 Amid Weak Petrochemical Margins and Energy Transition Pressures 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
